Thursday, October 2, 2014

Roth starts Trimel at buy

Roth starts Trimel at buy

October 16, 2012 by · Leave a Comment 

Tweet Roth Capital Partners has initiated coverage of Trimel Pharmaceuticals (TSX:TRL) with a “buy” rating and 12-month price target of $3, citing expectations for positive CompleoTRT data and a potential marketing partnership. The stock closed at $1.59 on Monday. CompleoTRT is a testosterone replacement for men. The testosterone market is already a $2-billion market, and […]

Trimel has positive early data from CompleoTRT trial

Trimel has positive early data from CompleoTRT trial

May 29, 2012 by · Leave a Comment 

Tweet Trimel Pharmaceuticals (TSX:TRL) has completed a preliminary review of early data from a Phase 3 clinical trial, indicating that 79.9% of patients treated with CompleoTRT achieved an average serum testosterone (AST) level within the normal range. The company said the results exceed the threshold required by the FDA to confirm the efficacy of a […]

Email Newsletters with Constant Contact
Google+